Data pertaining to the post-vaccination period including adverse events and effect of the vaccine on inflammatory bowel disease activity (n=105)
| All subjects (n=105) | NIS (n=28) | IS (n=77) | p Value | |
| 2009/2010 Seasonal influenza vaccine | 84 (80%) | 24 (86%) | 60 (78%) | 0.4 |
| H1N1 contact | 7 (7%) | 3 (11%) | 4 (5%) | 0.4 |
| Increased risk occupation | 20 (19%) | 5 (18%) | 15 (20%) | 0.9 |
| Median (range) weeks between visits | 5.3 (3–11) | 5.1 (2.9–10) | 5.6 (2.9–11) | 0.9 |
| Minor post-vaccination symptoms | 13 (12%) | 4 (14%) | 9 (12%) | 0.7 |
| Respiratory tract or influenza-like illness within 6 months | 6 (6%) | 2 (7%) | 4 (5%) | 0.7 |
| Increase in IBD disease activity indices post-vaccination | 12 (11%) | 1 (4%) | 11 (14%) | 0.2 |
| Change in IBD medications post-vaccination | 3 (3%) | 0 (0%) | 3 (4%) | 0.6 |
IBD, inflammatory bowel disease; IS, immunosuppressed; NIS, non-immunosuppressed.